Table 4.

Adjusted association between IGF variables and HPV positivity among controls

IGF markerOverall positivity
High-risk HPV types
HPV-16/HPV-18
OR (95% CI)PtrendOR (95% CI)PtrendOR (95% CI)Ptrend
Age adjusted*
IGF-I (quartiles)
    Q11.00 (reference)0.8531.00 (reference)0.9901.00 (reference)0.138
    Q21.26 (0.72-2.20)0.84 (0.42-1.68)0.40 (0.13-1.26)
    Q30.88 (0.49-1.57)0.68 (0.34-1.36)0.43 (0.15-1.25)
    Q41.17 (0.65-2.10)0.96 (0.48-1.92)0.38 (0.12-1.13)
IGFBP-3 (quartiles)
    Q11.00 (reference)0.4031.00 (reference)0.2521.00 (reference)0.883
    Q21.18 (0.70-2.00)1.75 (0.90-3.39)1.81 (0.63-5.19)
    Q31.08 (0.64-1.83)1.28 (0.65-2.51)0.72 (0.21-2.47)
    Q41.29 (0.77-2.16)1.68 (0.87-3.23)1.38 (0.47-4.03)
Adjusted for age and additional empirical and a priori confounders
IGF-I (quartiles)
    Q11.00 (reference)0.6311.00 (reference)0.6071.00 (reference)0.044
    Q21.45 (0.76-2.79)0.86 (0.38-1.95)0.39 (0.09-1.53)
    Q30.75 (0.37-1.52)0.49 (0.21-1.18)0.22 (0.06-0.90)
    Q41.02 (0.48-2.13)0.78 (0.32-1.93)0.20 (0.05-0.87)
IGFBP-3 (quartiles)
    Q11.00 (reference)0.3471.00 (reference)0.2891.00 (reference)0.555
    Q21.22 (0.65-2.27)1.89 (0.87-4.10)2.74 (0.80-9.37)
    Q31.15 (0.60-2.18)1.40 (0.62-3.19)1.08 (0.25-7.54)
    Q41.40 (0.73-2.66)1.81 (0.80-4.11)1.96 (0.51-7.54)
  • * Analyses adjusted for age group (<25, 25-29, 30-34, 35-39, 40-44, 45-49, and ≥50 y).

  • Analyses adjusted for age group (as above), ethnicity (French Canadian, English Canadian, Other), age at first intercourse (<16, 16-17, 18, >19 y), number of sexual partners (1, 2-4, 5-8, and >8 partners), cigarette smoking (current, former, never), oral contraceptive use (never, ever), use of hormones to treat menopause/infertility (never, ever), age at menarche (<12, 12, 13, 14+ years), and mutual adjustment for IGF-I and IGFBP-3 according to the quartiles among controls (same cutoff points as in Table 2).